Candriam S.C.A. Argenx Se Transaction History

Candriam S.C.A.

$17.1 Billion
Q3 2024

A detailed history of Candriam S.C.A. transactions in Argenx Se stock. As of the latest transaction made, Candriam S.C.A. holds 51,418 shares of ARGX stock, worth $33.7 Million. This represents 0.16% of its overall portfolio holdings.

Number of Shares

51,418

Previous 51,418 -0.0%

Holding current value

$33.7 Million

Previous $22.1 Million 26.12%

% of portfolio

0.16%

Previous 0.14%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 05, 2024	BUY	$356.01 - $451.55 $4.72 Million - $5.99 Million	13,265 Added 34.77%	51,418 $22.1 Million
Q1 2024 May 03, 2024	BUY	$356.95 - $413.29 $13.6 Million - $15.8 Million	38,153 New	38,153 $15 Million
Q4 2021 Feb 10, 2022	SELL	$272.01 - $353.03 $13.5 Million - $17.5 Million	-49,526 Closed	0 $0
Q2 2021 Jul 20, 2021	BUY	$257.11 - $319.92 $2.76 Million - $3.44 Million	10,753 Added 27.73%	49,526 $14.9 Million
Q1 2021 Apr 29, 2021	SELL	$268.3 - $380.31 $1,073 - $1,521	-4 Reduced 0.01%	38,773 $11 Million
Q4 2020 Jan 22, 2021	SELL	$248.13 - $308.36 $61,039 - $75,856	-246 Reduced 0.63%	38,777 $11.4 Million
Q3 2020 Oct 19, 2020	SELL	$215.51 - $272.51 $4.5 Million - $5.69 Million	-20,884 Reduced 34.86%	39,023 $10.2 Million
Q2 2020 Jul 23, 2020	BUY	$127.44 - $232.72 $6.57 Million - $12 Million	51,586 Added 619.95%	59,907 $13.5 Million
Q1 2020 May 26, 2020	BUY	$108.83 - $165.23 $979 - $1,487	9 Added 0.11%	8,321 $1.31 Million
Q4 2019 Jan 21, 2020	BUY	$106.59 - $164.21 $885,976 - $1.36 Million	8,312 New	8,312 $1,000

Others Institutions Holding ARGX

# of Institutions

403

Shares Held

30.8M

Call Options Held

376K

Put Options Held

489K

View Full List

About ARGENX SE

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $36.3B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

More about ARGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.

Account